NYSE American
No company description is available yet.
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
Where price sits today against its own history. A description, not a forecast.
Company figures as of Oct 23, 2026.
Price targets are opinions and tend to lean optimistic. Only 2 analysts cover it, so one view moves the average.
Average return in each calendar month, Nov 30, 2022 to Sep 30, 2026. 4 years is 4 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
| Year | J | F | M | A | M | J | J | A | S | O | N | D | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −14 | +11 | −2 | +83 | −21 | −12 | −16 | +19 | −10 | +7% | |||
| 2025 | −27 | +13 | −24 | +23 | −65 | −7 | +3 | −8 | −1 | −23 | −14 | −22 | −88% |
| 2024 | +16 | −7 | +1 | −14 | −38 | −6 | −1 | +1 | −77 | +6 | −1 | +22 | −84% |
| 2023 | +100 | −1 | −22 | −10 | +10 | +45 | −33 | −22 | +3 | −17 | +34 | −28 | −5% |
| 2022 | −5 | −37 | −40% |
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
As reported in the company's SEC filings. Latest: Q2 FY2026, ended Jun 30, 2026.
| Q3 FY2024Sep 30, 2024 | Q4 FY2024Dec 31, 2024 | Q1 FY2025Mar 31, 2025 | Q2 FY2025Jun 30, 2025 | Q3 FY2025Sep 30, 2025 | Q4 FY2025Dec 31, 2025 | Q1 FY2026Mar 31, 2026 | Q2 FY2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | ···· | ···· | ···· | ···· | ···· | ···· | ···· | $0.0 |
| vs a year before | ···· | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating income | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$3.3M |
| Net income | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$3.2M |
| EPS, diluted | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −0.07 |
| vs a year before | ···· | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cash flow | ||||||||
| From operations | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$3.1M |
| At period end | ||||||||
| Cash | ···· | ···· | ···· | ···· | ···· | ···· | ···· | $11.3M |
| Shareholders' equity | ···· | ···· | ···· | ···· | ···· | ···· | ···· | $12.2M |
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
Publication of Phase 2b trial results in prestigious Nature Medicine journal validates the VIRAGE study and demonstrates clinical efficacy of VCN-01 in combination therapy. The company is advancing to Phase 2a VIRAGE2 trial with more frequent dosing, and has received multiple regulatory designations (orphan drug, rare pediatric disease, FDA fast track). These developments support continued clinical development and potential future pivotal trials.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.